



Interim Report

Q3 2025

Monday 27 October 2025, 06:00 PM CET

DanCann
Pharma



DanCann Pharma A/S

CVR No.: 3942 6005

Rugvænget 5, DK-6823,
Ansager, Denmark

Tel.: +45 6916 0393
info@dancann.com

TABLE OF CONTENTS:

Interim Report Q3 2025

03	An introduction to DanCann Pharma A/S
04	Interim CEO & Chairman's Statement
05	Financial Performance
06	DCP Group Product Portfolio and Pipeline (2025)
07	Active Portfolio Overview
08	Regulatory Highlights from the Quarter
09	Ensuring Continued Share Trading After Delisting
10	Group Key Figures
11	About the Q2 Interim Report
12	Group Income Statement
13	Group Balance Sheet
14	Group Cash Flow Statement
15	Parent Income Statement
16	Parent Balance Sheet
17	Parent Cash Flow Statement

DISCLAIMER:

Forward looking statements.

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the

Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

An Introduction to DanCann Pharma A/S

DanCann Pharma A/S (“DanCann Pharma” or the “Company”) is a fully licensed commercial niche EU–GxP regulatory distribution company focusing on market access, sourcing and distribution, specialized in cannabinoids, with the subsidiary CannGros ApS.

Strategic Focus on Profitability and Capital Efficiency

Markets

	+1,600 unique patients	More than 500 doctors have prescribed cannabinoid treatment	Growth market, low competition and solid profitability
	+4,700 prescriptions (Q)		
	+12.7 million mg active substance (Q)		
	*All numbers are latest public figures.		


Commercial Focus

Business Development and Sales	Supply chain (sourcing and distribution)	Regulatory and Medical Affairs	Market access and data
--------------------------------	--	--------------------------------	------------------------

Activities

Import of medicinal products and narcotics	Secondary re-packaging	Warehouse, logistics and shipping	Labeling and batch release
--	------------------------	-----------------------------------	----------------------------

Cannabinoids



Medicinal Cannabis (Rx)

Medical Devices

Consumer (OTC/DTC)



Under the Danish Pilot Programme with Medicinal Cannabis (Danish Medicines Agency)

Revolutionize health and quality of life for patients with challenges

Our Customer Base:
Wholesalers (pharmacies, hospitals/healthcare facilities) and Manufacturers/Intermediate Manufacturers

Interim CEO & Chairman’s Statement

The third quarter has been eventful and transformative, and I would like to take this opportunity to shed some light on recent developments within the Company.

The Business

Throughout the year, the Company has continued to demonstrate steady progress in as well commercial traction as in cost-based optimization.

From the start of the year the market was characterized by volatility and lower prices. Since then, conditions have gradually stabilized, and the business has adapted to the competitive landscape that emerged towards the end of last year.

While profitability has not yet been achieved, the Company remains committed to implementing initiatives aimed at further improving operational performance and driving sustainable earnings over time.

Changes to the Organization

Our founder and long-standing Chief Executive Officer, Mr. Jeppe Krog Rasmussen, has stepped down from his position to pursue new professional opportunities. Jeppe founded DanCann Pharma with a clear mission: to bring cannabinoid-based medicines to patients in need. Under his leadership, the Company successfully navigated its formative years, obtained regulatory approvals, established production infrastructure, and positioned itself as a trusted operator within a complex and highly regulated industry.

To ensure a seamless transition, Jeppe will continue to support the Company in an advisory capacity during the transition period.

On behalf of the Board of Directors, I wish to express our sincere appreciation to Jeppe for his vision, relentless dedication, and many years of service to DanCann Pharma.

In an interim period, I will assume the position of Chief Executive Officer, as appointed by the Board, with the intention of nominating Mr. Peter Hauberg Søndergaard, formerly Chief Financial Officer of DanCann Pharma, as the Company’s new Chief Executive Officer in the coming months. Peter brings deep financial acumen and a strong record of operational discipline.

As CEO, Peter will focus on steering the Company through the voluntary delisting process, strengthening operational efficiency, and executing the long-term Maturity2028 strategy. His leadership will emphasize disciplined capital allocation, profitability, and sustainable value creation. The Board warmly welcomes Peter in his new capacity and looks forward to his continued leadership in this next phase of DanCann Pharma’s development.

Divestment of Biotech Pharm 1 (BP1)

The Company has for some time been actively engaged in the potential divestment of its production facility, Biotech Pharm 1 (“BP1”). While the process has taken longer than initially anticipated, there remains tangible interest from several parties.




It is important to note that such transactions are inherently complex and time-consuming, particularly given that prospective buyers face the prospect of additional capital investment to commercialize the facility and establish supporting organizational structures.

The Company remains committed to keeping the market informed as material developments occur.


Yours sincerely,
Carsten Trads
Interim Chief Executive Officer & Chairman
DanCann Pharma A/S

Financial Performance


Revenue (QoQ) in 1,000 DKK




Revenue (YoY) in 1,000 DKK



EBITDA (QoQ) in 1,000 DKK




EBITDA* (YoY) in 1,000 DKK



Gross Revenue: Gross Revenue refers to the total revenue generated prior to any deductions for price reductions, rebates, or returned goods from wholesalers due to product expiry.

DCP Group Product Portfolio and Pipeline (2025):



● Exclusive product offerings developed in collaboration with partners

● Partner-created products incorporating DanCann Pharma’s commercial assests

Active Portfolio Overview

Here's an overview of the active DCP Group product portfolio.



Bedica® CannGros
Granulate
Dronabinol (THC) 140 mg
Cannabidiol (CBD) 10 mg



Bediol® CannGros
Granulate
Dronabinol (THC) 63 mg
Cannabidiol (CBD) 80 mg



Bedrolite® CannGros
Granulate
Dronabinol (THC) ≤10 mg
Cannabidiol (CBD) 75 mg




Bedrobinol® CannGros
Flos
Dronabinol (THC) 135 mg
Cannabidiol (CBD) ≤10 mg



Bedrocan® CannGros
Flos
Dronabinol (THC) 220 mg
Cannabidiol (CBD) 10 mg

Regulatory Highlights from the Quarter



Ensuring Continued Share Trading After Delisting

Following the approval on EGM October 21 2025 DanCann will be delisted from Spotlight.

The shares can be traded on Spotlight Stock Market in accordance with Spotlight Stock Market’s Regulations up to and including the last trading day.

It was noted that a delisting of the Company’s shares from trading on Spotlight Stock Market will imply that the Company’s shares cannot be traded on Spotlight Stock Market, and trading in the Company’s shares will take place over-the-counter (“OTC”). The process for trading is described after the time plan.

Tentative time plan for the delisting:	
7 January 2026	Application for delisting submitted to Spotlight Stock Market
8 January 2026	Spotlight Stock Market approves the delisting and announces the last day of trading of the Company's shares on Spotlight Stock Market
8 January 2026	The Company publishes a press release regarding the approval of the delisting and the last day of trading
22 January 2026	Expected last day of trading for the Company's shares on Spotlight Stock Market

Following the planned delisting of the Company's shares from the stock exchange, we recognise the importance of providing our shareholders with a transparent and practical way to continue trading their shares.

To facilitate this, the Company intends to establish a dedicated section on our corporate website — within the Investor Relations area — where shareholders who wish to buy or sell shares can register their interest. This platform will provide an overview of potential buyers and sellers and thereby enable continued trading between shareholders in a structured and accessible manner.

In addition, the website will include detailed guidance on how to have shares registered by name (if not already done) and clear instructions on the practical process for trading shares once the delisting has taken effect.

Through these initiatives, the Company aims to ensure that shareholders retain flexibility and transparency in their ability to manage their investments, even after the shares are no longer publicly listed.






Summary: Group key figures Q3 2025

DKK 1 000	01/07/25 – 30/09/25	01/07/24 – 30/09/24	01/01/25 – 30/09/25	01/01/24 – 30/09/24	2024 Full year
Net sales	1,618	1,855	3,045	6,406	7,371
EBITDA	-1,038	-901	-5,751	-3,076	-5,099
OPERATING PROFIT/LOSS (EBIT)	-1,535	-1,420	-7,245	-4,602	-7,124
Result per share (DKK)	-0.3915	-0.0002	-1.8566	-0.0004	-0.0021
Equity ratio	0.55	0.85	0.55	0.85	0.86

Number of Shares 30.09.2025 – 3,991,052 (166,626,687)
Result per share = Result for the period / weighted average number of shares
Equity ratio = Equity / Total assets

Gross Revenue
Gross Revenue refers to the total revenue generated prior to any deductions for price reductions, rebates, or returned goods from wholesalers due to product expiry.



About the Q3 Interim Report

DANCANN PHARMA A/S was formed in March 2018.

The fiscal year is 1st of January to December 31. DanCann Pharma A/S acquired CannGros ApS on October 18, 2021, and established the OTC Group ApS on December 5, 2024. This interim report deals with the consolidated financials for the group DanCann Pharma A/S, company reg. no. 39 42 60 05, CannGros ApS, company reg. no. 39 03 94 51 and OTC Group ApS, company reg. no. 45 25 56 89. Financial statements for DanCann Pharma A/S as parent company are included.

Auditor’s review

This interim report has not been audited.

Accounting policy

The interim report has been prepared in accordance with the provisions of the Danish Financial Statements Act for enterprises in reporting class B, medium-sized enterprises.

Revenue and results

The consolidated revenue was 1,618 (1,855) in Q3 2025. As well, in Q3 2025, the own consolidated work capitalized was 0 (0), the cost of sales was 1,025 (825), and other external expenses were 497 (829). The consolidated operating profit (EBIT) for Q3 2025 was -1,535 (-1,420).

Balance sheet

The consolidated total assets at the end of the period amounted to 12,798 (15,716). Consolidated fixed assets amounted to 10,562 (12,679). Consolidated current assets were 2,237 (3,037) and consisted of cash and cash equivalents and receivables from corporation tax and refundable VAT.

At the end of the period, the equity amounted to 7,064 (13,310). Provisions amounted to 0 (0), and current liabilities amounted to 5,734 (2,407).

Cash flow

In Q3 2025 the consolidated cash flow was -1,110 (5,748). Cash flow from net investments was 0 (0).

Shares

The shares of DanCann Pharma A/S were listed on Spotlight Stock Market on November 12, 2020. DanCann Pharma A/S’ shares are traded under the ticker “DANCAN” with ISIN code ISIN DK0061410487. On September 30, 2025, the total number of shares in DanCann Pharma A/S was 3,991,052 (141,626,688).

All shares carry the same rights. The nominal value as of September 30 2025 was DKK 1.00 per share.

Warrants for the Executive Management team and Board of Directors

The Board of Directors has granted warrants for the management team. 254,286 warrants are still vaild and can be exercised until 2025. The warrants are vesting in three equal stages over the next three years. The Company has granted warrants to the Board of Directors. 150,000 warrants are still valid and can be exercised until 2025. The warrants are vesting in three equal stages over the next three years. Each warrant grants the right to subscribe for one share.

Shareholders

Shareholders with more than 5% of the votes and capital on September 30, 2025.

Name	Number of Shares	Proportion of votes and capital
JEQ Capital AB	104,876	9.89%
Others	3,596,147	90.11%
	3,991,052	100.00%

Operational risks and uncertainties

The risks and uncertainties that DanCann Pharma operations are exposed to are related to factors such as development, competition, permissions, capital requirements, customers, suppliers/manufacturers, currencies, and interest rates. During the current period, no significant changes in the risk factors or any uncertainties have occurred.

Group income statement

DKK 1 000	01/07/25 – 30/09/25	01/07/24 – 30/09/24	01/01/25 – 30/09/25	01/01/24 – 30/09/24	2024 Full year
Net sales	1,618	1,855	3,045	6,406	7,371
Own work capitalised	–	–	–	–	–
Cost of sales	–1,025	–825	–2,381	–2,889	–3,581
Other operating income	–	–2	–	–13	–6
Other external expenses	–497	–829	–2,746	–2,903	–4,020
GROSS PROFIT/LOSS	96	199	–2,082	609	–228
Staff expenses	–1,134	–1,100	–3,669	–3,686	–4,871
OPERATING PROFIT/LOSS BEFORE DEPR. AND AMORT. (EBITDA)	–1,038	–901	–5,751	–3,076	–5,099
Depreciation and amortisation	–496	–519	–1,494	–1,526	–2,026
OPERATING PROFIT/LOSS (EBIT)	–1,535	–1,420	–7,245	–4,602	–7,124
Financial income	67	–37	101	6	38
Financial expenses	–95	–293	–266	–1,177	–1,242
PROFIT/LOSS BEFORE TAX	–1,562	–1,750	–7,410	–5,773	–8,328
Tax on profit/loss for the period	–	–1,104	–	–	–
NET PROFIT/LOSS AFTER TAX	–1,562	–2,855	–7,410	–5,773	–8,328



Group balance sheet

DKK 1 000	01/07/25 – 30/09/25	01/07/24 – 30/09/24	01/01/25 – 30/09/25	01/01/24 – 30/09/24	2024 Full year
Goodwill	7,590	8,990	7,590	8,990	8,693
Distribution rights	–	–	–	–	–
Development projects in progress and prepayments	–	–	–	–	–
Intangible assets	7,590	8,990	7,590	8,990	8,693
Other plant, machinery, tools and equipment	635	899	635	899	832
Leasehold improvements	1,916	2,371	1,916	2,371	2,257
Tangible fixed assets in progress and prepay.	98	98	98	98	98
Property, plant and equipment	2,650	3,368	2,650	3,368	3,187
Investments in subsidiaries	–	–	–	–	–
Rent deposit and other receivables	322	322	322	322	322
Financial non-current assets	322	322	322	322	322
NON-CURRENT ASSETS	10,562	12,679	10,562	12,679	12,202
Raw materials and consumables	–	2	–	2	–
Finished goods and goods for resale	–	62	–	62	–
Prepayments	335	335	335	335	335
Inventories	335	399	335	399	335
Trade receivables	758	1,587	758	1,587	136
Other receivables	–79	267	–79	267	551
Corporation tax receivables	140	–	140	–	140
Deferred tax	–	–	–	–	–
Joint tax contribution receivable	–	–	–	–	–
Prepayments and accrued income	584	583	584	583	337
Receivables	1,403	2,437	1,403	2,437	1,027

DKK 1 000	01/07/25 – 30/09/25	01/07/24 – 30/09/24	01/01/25 – 30/09/25	01/01/24 – 30/09/24	2024 Full year
Cash and cash equivalents	498	201	498	201	3,472
CURRENT ASSETS	2,237	3,037	2,237	3,037	4,834
ASSETS	12,798	15,716	12,798	15,716	17,036
Share capital	3,991	15,411	3,991	15,411	3,991
Share premium	–	995	–	995	–3,628
Reserve	18,452	4,582	18,452	4,582	18,452
Retained profit	–15,378	–7,678	–15,378	–7,678	–4,195
EQUITY	7,064	13,310	7,064	13,310	14,620
Provision for deferred tax	–	–	–	–	–
PROVISION	–	–	–	–	–
Lease liabilities	–	–	–	–	–
Trade payables	2,026	1,433	2,026	1,433	1,253
Corporation tax payable	0	0	0	0	0
Other liabilities	3,708	975	3,708	975	1,163
Current liabilities	5,734	2,407	5,734	2,407	2,415
LIABILITIES	5,734	2,407	5,734	2,407	2,415
EQUITY AND LIABILITIES	12,798	15,717	12,798	15,717	17,036

Group cash flow statement

DKK 1 000	01/07/25 – 30/09/25	01/07/24 – 30/09/24	01/01/25 – 30/09/25	01/01/24 – 30/09/24	2024 Full year
Profit/loss for the year	-1,208	-3,434	-8,365	-6,846	-8,624
Depreciation and amortisation, reversed	496	519	1,494	1,526	2,026
Provision reserved	-	-	-	-	-
Net equity purchase, Canngros ApS	-	-	-	-	-
Net equity purchase, Canngros ApS	-	-	-	-	-
Tax profit/loss, reversed	-	-	-	-	-
Corporation tax received	-	-	-	-	-
Change in inventories	-	-62	-	-58	6
Change in receivables	472	5,273	2,387	228	1,637
Change in current liabilities	-869	-3,085	1,318	-239	-230
Other cash flows from operating activities	-	-	-	-	-
CASH FLOWS FROM OPERATING ACTIVITY	-1,110	-789	-3,165	-5,389	-5,186
Purchase of intangible assets	-	-	-	-	-
Purchase of property, plant and equipment	-	-	-	-	-
Sale of property, plant and equipment	-	-	-	-	-
Purchase of leaseholds improvements	-	-	-	-	-
Purchase of tangible fixed assets in progress and prep	-	-	-	-	-
Purchase of financial assets	-	21	-	36	66
CASH FLOWS FROM INVESTING ACTIVITY	-	21	-	36	66

DKK 1 000	01/07/25 – 30/09/25	01/07/24 – 30/09/24	01/01/25 – 30/09/25	01/01/24 – 30/09/24	2024 Full year
Increase loans	-	-	-	-	-
Decrease Loans	-	-	-	-	-
Increase leasing debt	-	-	-	-	-
Other capital items – capital raising costs	-	-4,185	-	-5,106	-4,864
Share capital payments	-	10,701	-	11,638	11,638
CASH FLOWS FROM FINANCING ACTIVITIES	-	6,516	-	6,532	6,774
CHANGE IN CASH AND CASH EQUIVALENTS	-1,110	5,748	-3,165	1,179	1,654
Cash and cash equivalents at beginning	1,607	-2,560	3,663	2,009	2,009
CASH AND CASH EQUIVALENTS AT END	498	3,188	498	3,188	3,663

Parent income statement

DKK 1 000	01/07/25 – 30/09/25	01/07/24 – 30/09/24	01/01/25 – 30/09/25	01/01/24 – 30/09/24	2024 Full year
Net sales	-	-	-	-	-
Own work capitalised	-	-	-	-	-
Cost of sales	-	-	-	-	-
Other operating income	-	-2	-	-13	-6
Other external expenses	-412	621	-1,301	1,611	-53
Gross Profit/Loss	-412	618	-1,301	1,605	-51
Staff expenses	-1,134	-1,100	-3,669	-3,686	-4,871
OPERATING PROFIT/LOSS BEFORE DEPR. AND AMORT. (EBITDA)	-1,547	-482	-4,970	-2,081	-4,923
Depreciation and amortisation	-496	-519	-1,494	-1,526	-2,026
OPERATING PROFIT/LOSS (EBIT)	-2,043	-1,001	-6,464	-3,607	-6,948
Financial income	75	-	129	84	140
Financial expenses	-95	-293	-266	-1,177	-1,242
PROFIT/LOSS BEFORE TAX	-1,709	-1,873	-7,556	-5,773	-8,346
Tax on profit/loss for the period	-	-965	-	-	-
NET PROFIT/LOSS AFTER TAX	-1,709	-2,838	-7,556	-5,773	-8,346



Parent balance sheet

DKK 1 000	01/07/25 – 30/09/25	01/07/24 – 30/09/24	01/01/25 – 30/09/25	01/01/24 – 30/09/24	2024 Full year
Goodwill	–	–	–	–	–
Distribution rights	–	–	–	–	–
Development projects in progress and prepay- ments	–	–	–	–	0
Intangible assets	–	–	–	–	0
Other plant, machinery, tools and equipment	635	899	635	899	832
Leasehold improvements	1,916	2,371	1,916	2,371	2,257
Tangible fixed assets in progress and prepay.	98	98	98	98	98
Property, plant and equipment	2,650	3,368	2,650	3,368	3,187
Investments in subsidiaries	7,988	9,402	7,988	9,402	9,900
Rent deposit and other receivables	322	322	322	322	322
Financial non-current assets	8,310	9,724	8,310	9,724	10,222
NON-CURRENT ASSETS	10,960	13,091	10,960	13,091	13,408
Raw materials and consumables	–	–	–	–	–
Finished goods and goods for resale	–	–	–	–	–
Prepayments	–	–	–	–	–
Inventories	–	–	–	–	–
Trade receivables	–	–	–	–	–
Other receivables	–79	267	–79	267	404
Corporation tax receivables	140	–	140	–	140
Deferred tax	–	–	–	–	–
Joint tax contribution receivable	–	–	–	–	–
Prepayments and accrued income	469	500	469	500	324

DKK 1 000	01/07/25 – 30/09/25	01/07/24 – 30/09/24	01/01/25 – 30/09/25	01/01/24 – 30/09/24	2024 Full year
Receivables	530	767	530	767	868
Cash and cash equivalents	835	814	835	814	1,698
CURRENT ASSETS	1,365	1,581	1,365	1,581	2,566
ASSETS	12,325	14,672	12,325	14,672	15,975
Share capital	3,991	15,411	3,991	15,411	3,991
Share premium	–	995	–	995	–3,628
Reserve	18,452	4,582	18,452	4,582	18,452
Retained profit	–15,378	–7,678	–15,378	–7,678	–4,195
EQUITY	7,064	13,310	7,064	13,310	14,620
Provision for deferred tax	–	–	–	–	–
PROVISION	–	–	–	–	–
Lease liabilities	–	–	–	–	–
Trade payables	1,833	736	1,833	736	1,125
Corporation tax payable	–	–	–	–	–
Other liabilities	3,428	626	3,428	626	230
Current liabilities	5,261	1,362	5,261	1,362	1,355
LIABILITIES	5,261	1,362	5,261	1,362	1,355
EQUITY AND LIABILITIES	12,325	14,672	12,325	14,672	15,975

Parent cash flow statement

DKK 1 000	01/07/25 – 30/09/25	01/07/24 – 30/09/24	01/01/25 – 30/09/25	01/01/24 – 30/09/24	2024 Full year
Profit/loss for the year	-1,709	-2,838	-7,556	-5,773	-8,346
Depreciation and amortisation, reversed	496	519	1,494	1,526	2,026
Provision reserved	-	-	-	-	-
Cash from purchase, Canngros ApS	-	-	-	-	-
Net equity purchase, Canngros ApS	-	-	-	-	-
Tax profit/loss, reversed	-	-	-	-	-
Corporation tax received	-	-	-	-	-
Change in inventories	-	-	-	-	-
Change in receivables	638	3,778	3,101	1,043	941
Change in current liabilities	-355	-3,007	1,907	-456	-464
Other cash flows from operating activities	-	-	-	-	-
CASH FLOWS FROM OPERATING ACTIVITY	-929	-1,548	-1,054	-3,660	-5,843
Purchase of intangible assets	-	-	-	-	-
Purchase of property, plant and equipment	-	-	-	-	-
Sale of property, plant and equipment	-	-	-	-	-
Purchase of leaseholds improvements	-	-	-	-	-
Purchase of tangible fixed assets in progress and prepayment	-	-	-	-	-
Purchase of financial assets	-	21	-	36	66
CASH FLOWS FROM INVESTING ACTIVITY	-	21	-	36	66

DKK 1 000	01/07/25 – 30/09/25	01/07/24 – 30/09/24	01/01/25 – 30/09/25	01/01/24 – 30/09/24	2024 Full year
Increase loans	-	-	-	-	-
Decrease Loans	-	-	-	-	-
Increase leasing debt	-	-	-	-	-
Other capital items – capital raising costs	-	-4,185	-	-5,106	-4,864
Share capital payments	-	10,701	-	11,638	11,638
CASH FLOWS FROM FINANCING ACTIVITIES	-	6,516	-	6,532	6,774
CHANGE IN CASH AND CASH EQUIVALENTS	-929	4,989	-1,054	2,908	997
Cash and cash equivalents at beginning	1,764	-1,189	1,889	892	892
CASH AND CASH EQUIVALENTS AT END	835	3,800	835	3,800	1,889

Better than yesterday

We want to revolutionize health care for everyone and ensure that no one experiencing pain or trauma gets left behind.

DanCann Pharma is all about challenging the status quo. We saw an issue in our healthcare system and are now working with determination to change it.



DanCann Pharma A/S

CVR No.: 3942 6005

Rugvænget 5, DK-6823,
Ansager, Denmark

Tel.: +45 6916 0393
info@dancann.com
www.dancann.com

